Our team
Board of Directors
Luis Sánchez-Lafuente
Chairman
Former Chief Executive Officer and co-owner of Laboratorios Gelos, SA. President of AB Biotics, SA
Carles Domènech
Executive chairman
Executive Chairman, CSO and co-Founder of Ability Pharmaceuticals, SL
José Manuel Valadés
General secretary
Lawyer, partner and founder of the law firm Alliant Abogados
Miquel Àngel Bonachera
Chief executive officer and co-founder of AB Biotics, SA.
BSc/MSc in biochemistry and MBA.
BSc/MSc in biochemistry and MBA.
Sergi Audivert
Chief executive officer and co-founder of AB Biotics, SA.
BSc/MSc in food technology and MBA.
BSc/MSc in food technology and MBA.
Sara Secall
Operating Partner & Life Sciences Investment Director of Inveready Asset Management
Estanislao Tejeda
Partner, Global Strategic Deals at NTT DATA Europe & LATAM
Shermaine Tilley
Managing Partner Funds I, II & III, CTILife Science Fund
PhD in biochemistry from the Johns Hopkins University School of Medicine, MBA from the University of Toronto
LATEST NEWS
05.06.2025
Press Release
AbilityPharma’s IBRILATAZAR (ABTL0812) doubles overall survival in patients with squamous non-small cell lung cancer + info
09.09.2024
Press Release
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info
30.07.2024
Press Release
AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info
16.07.2024
Press Release
AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + info
11.03.2024
Press Release
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023
Press Release
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022
Press Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022
Press Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022
Press Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
